On August 30th, 2017, MLabs launched four new next-generation sequencing (NGS) panels including the Lung Cancer NGS Panel, the Colorectal Cancer NGS Panel, the Melanoma NGS Panel and the Solid Tumor NGS Panel.  By detecting mutations, gene amplifications and gene fusions, these panels not only cover standard of care molecular alterations for solid tumors, but also the vast majority of those that are relevant for clinical trial enrollment and other emerging therapeutic options. This comprehensive information is delivered with a faster turn-around time than most NGS panels – 6 to 13 days with most results available within 8 days of receipt. In addition, these panels have been optimized to be run on small formalin-fixed paraffin-embedded biopsies and aspirates with a limited number of neoplastic cells. For cases with inadequate cell blocks and exhausted tissue blocks, these panels can be run on Diff-Quik or Pap stained aspirate smears or even the diagnostic H&E slide itself (following digital imaging). A full description of the tests including the molecular alterations covered is available in the MLabs online Clinical Test Catalog at

To view each Panel, please click on the links below:

Lung Cancer NGS Panel  
Colorectal Cancer NGS Panel  
Melanoma NGS Panel   
Solid Tumor NGS Panel